ASLAN Pharmaceuticals Presents New Data From Phase 2b Study of Eblasakimab in Atopic Dermatitis ...

Data presented during the late-breaker oral presentation of the TREK-AD study demonstrate e blasakimab’s potential as the first biologic in moderate-to-severe atopic dermatitis to demonstrate a competitive efficacy profile with

Related Keywords

California ,United States ,Russia ,Singapore ,Oregon ,Ukraine ,Ericl Simpson ,Francesj Storrs ,Ashleyr Robinson ,Alex Kaoukhov ,Emma Thompson ,Exchange Commission On ,Spurwing Communications ,Linkedin ,Exchange Commission ,Science University ,Pharmaceuticals Nasdaq ,European Academy Of Dermatology ,Company Us Securities ,Commission File No ,Lifesci Advisors ,Oregon Health ,Venereology Congress ,Company Annual Report On Form ,European Academy ,Medical Dermatology ,Lead Investigator ,Eczema Area ,Severity Index ,Chief Medical Officer ,Investigator Global Assessment ,Atopic Dermatitis ,San Mateo ,Sci Advisors ,Commission File ,Annual Report ,Region ,